However, the most successful pharmacological treatment of AML is still all-trans retinoic acid (ATRA)-based differentiation therapy of acute promyelocytic leukemia (APL), a particular subtype of AML defined by the PML-RARA rearrangement. This evidence concerns the gene PML and acute promyelocytic leukemia.